Literature DB >> 16830247

[Palliative chemotherapy and CUP-syndrome: medical intentions versus patients' attitudes in decision making].

Stephan Iglseder1.   

Abstract

The following case report is about a 55 year old male patient with CUP-syndrome. After developing a malignant bowel obstruction he received five cycles of a palliative chemotherapy with oxaliplatin and irinotecan. The focus is on medical intentions and goals concerning palliative chemotherapy and on discussing patients' attitudes towards chemotherapy. Communication is identified as fundamental skill in shared decision making. On the one hand it improves Patients' satisfaction and palliative care and on the other hand it reduces psychological and existential suffering. In tumors of unknown primary site regimens with different combinations of Platin, Taxol, Etoposide, Irinotecan and Gemcitabine showed responses up to 46% and a survival benefit with an overall median survival up to 12 months and even long term survival.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16830247     DOI: 10.1007/s10354-006-0290-9

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  16 in total

Review 1.  A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site.

Authors:  Yeon Hee Park; Baek-Yeol Ryoo; Seong-Jun Choi; Sung Hyun Yang; Heung-Tae Kim
Journal:  Jpn J Clin Oncol       Date:  2004-11       Impact factor: 3.019

2.  What are cancer patients' preferences about treatment at the end of life, and who should start talking about it? A comparison with healthy people and medical staff.

Authors:  S Sahm; R Will; G Hommel
Journal:  Support Care Cancer       Date:  2005-01-19       Impact factor: 3.603

3.  Cure me even if it kills me: preferences for invasive cancer treatment.

Authors:  Angela Fagerlin; Brian J Zikmund-Fisher; Peter A Ubel
Journal:  Med Decis Making       Date:  2005 Nov-Dec       Impact factor: 2.583

4.  Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-Operative Oncology Group Phase II Study.

Authors:  E Briasoulis; N Tsavaris; G Fountzilas; A Athanasiadis; P Kosmidis; D Bafaloukos; D Skarlos; E Samantas; N Pavlidis
Journal:  Oncology       Date:  1998 Sep-Oct       Impact factor: 2.935

5.  Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective?

Authors:  George Pentheroudakis; Evangelos Briasoulis; Vassilis Karavassilis; George Fountzilas; Nikolaos Xeros; George Samelis; Epaminondas Samantas; Nicholas Pavlidis
Journal:  Acta Oncol       Date:  2005       Impact factor: 4.089

Review 6.  [Prognosis and possibilities of treatment of inaugural metastases].

Authors:  Nicolas Penel
Journal:  Presse Med       Date:  2003-06-14       Impact factor: 1.228

7.  [Management of intestinal obstruction in advanced ovarian cancer an analysis of 57 cases].

Authors:  X Sun; X Li; H Li
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  1995-01

8.  Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public.

Authors:  M L Slevin; L Stubbs; H J Plant; P Wilson; W M Gregory; P J Armes; S M Downer
Journal:  BMJ       Date:  1990-06-02

Review 9.  Diagnostic and therapeutic management of cancer of an unknown primary.

Authors:  N Pavlidis; E Briasoulis; J Hainsworth; F A Greco
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

10.  Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site.

Authors:  A Piga; R Nortilli; G L Cetto; N Cardarelli; S Luzi Fedeli; G Fiorentini; M D'Aprile; F Giorgi; A P Parziale; A Contu; R Montironi; R Gesuita; F Carle; R Cellerino
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.